Source: Eur Respir J, 58 (6) 2003397; 10.1183/13993003.03397-2020



Rating:

Share or cite this content

Citations should be made in the following way:
Yoshio Nakahara, Naozumi Hashimoto, Koji Sakamoto, Atsushi Enomoto, Taylor S. Adams, Toyoharu Yokoi, Norihito Omote, Sergio Poli, Akira Ando, Keiko Wakahara, Atsushi Suzuki, Masahide Inoue, Akitoshi Hara, Yasuyuki Mizutani, Kazuyoshi Imaizumi, Tsutomu Kawabe, Ivan O. Rosas, Masahide Takahashi, Naftali Kaminski, Yoshinori Hasegawa. Fibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosis. Eur Respir J, 58 (6) 2003397; 10.1183/13993003.03397-2020

Member's Comments

No comment yet.

Related content which might interest you: Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Fibrocytes are a potential source of fibroblasts in idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 719s Year: 2007 Antioxidant and anti-inflammation effect of GHK-Cu in bleomycin-induced pulmonary fibrosis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis:  mechanistic insights and prognostic markers Year: 2018 Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 The anti-proliferative effects of apelin on pulmonary adventitial fibroblasts Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Antifibrosic effects of sulforaphane in human lung fibroblasts from idiopathic pulmonary fibrosis Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 The cross-talk between TGF-ß and periostin can be targeted for pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Role of endothelin in lung fibrosis Source: Eur Respir Rev 2008; 17: 145-150 Year: 2008 Angiogenic activity of sera from patients with various types of pulmonary fibrosis in relation to pulmonary functions Source: Annual Congress 2009 - Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation Year: 2009 Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells Source: Eur Respir J 2015; 45: 428-439 Year: 2015 Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI Source: Eur Respir J, 52 (3) 1702314; 10.1183/13993003.02314-2017 Year: 2018